CA9 and neoplasm: One of the drugs used, S4, has been shown to inhibit the tumor associated carbonic anhydrase IX and XII isoforms at low nanomolar levels, while having much less activity against the non-tumor associated cytosolic carbonic anhydrase isoforms [19].